Pinatuzumab vedotin

N/A

Report date: 2024/02/07 20:05:28

Base Information

Drug NamePinatuzumab vedotin

Drug Alias NameAnti-CD22-MCC-DM1DCDT 2980S antibody-drug conjugateDCDT 2980S ADCAnti-CD22-ADCRO-5541072-000 +[10]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsCD22 modulators

TargetsTubulinCD22

Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, Diffuse

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesNetherlands +[6]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGenentech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenentech Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, FollicularLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A